HFA Joins Global Coalition Calling for Physical Activity to Be Central to Obesity Medication Treatments

The statement arrives at a pivotal moment. With nearly 3 billion adults worldwide currently overweight or living with obesity—a figure projected to climb to 4 billion by 2035—the organizations acknowledge that GLP-1 treatments and similar medications represent meaningful progress in the global battle against obesity. But the statement from these groups is clear on one essential point: Medication alone is not enough.

What the Coalition Seeks

The statement outlines key actions for global policymakers and health-system leaders, including:

• Embedding obesity medications within integrated care models that include funded access to physical activity and nutrition support;

• Protecting and expanding investment in prevention infrastructure and community-based programs;

• Ensuring equitable access to both treatment and supportive services;

• Measuring outcomes beyond weight, including functional health and long-term maintenance; and

• Aligning health and economic policy to recognize the value of prevention.

A statement from the organizations said: "Obesity is a complex, chronic disease that requires a comprehensive and coordinated response. Medications can play an important role, but they are not a stand-alone solution. Their success will depend on whether they are integrated into systems that support prevention, long-term behavior change, and overall well-being."

The statement warns that relying on pharmacological treatment alone without lifestyle intervention risks a cascade of unintended consequences—including loss of muscle mass, diminished functional capacity, and widening health inequalities if access to supportive services remains unequal. In response, the coalition calls for a "wraparound" approach that pairs medication with sustained investment in physical activity, nutrition, and supportive environments.